Improved survival from lung cancer in British Columbia compared to Scotland-Are different treatment rates the whole story?

Lung Cancer

Volumn 64, Issue 3, 2009, Pages 358-366

  Erridge, Sara C ^a,b   Murray, Brian ^c   Williams, Linda ^b   Brewster, David ^b,c   Black, Roger ^c   Price, Allan ^a,b   Murray, Nevin ^d,e   Sheehan, Finbarr ^d,e  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemotherapy; Lung cancer; Population based; Radiotherapy; Surgery; Survival; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BIOLOGY; CANADA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DIET; FEMALE; HAZARD RATIO; HUMAN; LIFE EXPECTANCY; LIFESTYLE; LUNG LOBECTOMY; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PALLIATIVE THERAPY; POPULATION GENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEGMENTECTOMY; SMOKING; UNITED KINGDOM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC PROTOCOLS; BRITISH COLUMBIA; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LIFE EXPECTANCY; LUNG NEOPLASMS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SCOTLAND; SMALL CELL LUNG CARCINOMA; SMOKING; SURVIVAL ANALYSIS;

EID: 67349175637     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.10.002     Document Type: Article

References (68)

1. Erridge S., Moller H., Price A., and Brewster D. International comparisons of survival from lung cancer: pitfalls and warnings. Nat Clin Pract Oncol 4 10 (2007) 570-577
2. Anonymous. Five-year relative survival in Canada 1992. Canadian Cancer Statistics (2002)
3. Anonymous. Canadian Cancer Statistics 2008. Toronto; 2008.
4. Karim-Kos H., de Vries E., Soerjomataram I., Lemmens V., Siesling S., and Coebergh J. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44 10 (2008) 1345-1389
5. Information-Statistics-Division. Trends in Cancer Survival in Scotland 1997-2001 (2004)
6. Erridge S.C., Thomson C.S., Davidson J., Jones R.D., and Price A. Factors influencing the use of thoracic radiotherapy in lung cancer-an analysis of the 1995 Scottish lung cancer audit. Clin Oncol (R Coll Radiol) 14 3 (2002) 219-227
7. Fergusson R.J., Thomson C.S., Brewster D., Brown P., and Milroy R. Lung cancer: the importance of seeing a respiratory physician. Eur Respir J 21 (2003) 606-610
8. Gregor A., Thomson C.S., Brewster D.H., Stroner P.L., Davidson J., Fergusson R.J., et al. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax 56 3 (2001) 212-217
9. Coleman M.P., Rachet B., Woods L.M., Mitry E., Riga M., Cooper N., et al. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 90 7 (2004) 1367-1373
10. McDavid K., Tucker T.C., Sloggett A., and Coleman M.P. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med 163 18 (2003) 2135-2144
11. McLaren G., and Bain M. Deprivation and health in Scotland: insights from NHS data (1998), ISD Scotland Publications, Edinburgh
12. Hislop T., Coldman A., Olivotto I., D'yachkova Y., and Speers C. Local and regional therapy for women with breast cancer in British Columbia. Breast J 9 3 (2003) 192-199
13. Scottish-Executive-Health-Department. Radiotherapy activity planning for Scotland 2010-2015. Edinburgh; 2005.
14. Dickman P., Sloggett A., Hills M., and Hakulinen T. Regression models for relative survival. Stat Med 23 1 (2004) 51-64
15. Capocaccia R., Gatta G., Roazzi P., Carrani E., Santaquilani M., De Angelis R., et al. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 14 Suppl. 5 (2003) 14-27
16. Fu J.B., Kau T.Y., Severson R.K., and Kalemkerian G.P. Lung cancer in women: analysis of the SEER database. Chest 127 3 (2005) 768-777
17. Gadgeel S.M., Severson R.K., Kau Y., Graff J., Weiss L.K., and Kalemkerian G.P. Impact of race in lung cancer: analysis of temporal trends from a SEER database. Chest 120 1 (2001) 55-63
18. Calman-Hine. A policy framework for commissioning cancer services (1995), Department of Health o England and Wales, London
19. Imperatori A., Harrison R.N., Leitch D.N., Rovera F., Lepore G., Dionigi G., et al. Lung cancer in Teesside (UK) and Varese (Italy): a comparison of management and survival. Thorax 61 3 (2006) 232-239
20. Free C., Ellis M., Beggs L., Beggs D., Morgan S., and Baldwin D. Lung cancer outcomes at a UK cancer unit between 1998 and 2001. Lung Cancer 57 2 (2007) 222-228
21. Delaney G., Barton M., Jacob S., and Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 4 2 (2003) 120-128
22. Barbera L., Zhang-Salomons J., Huang J., Tyldesley S., and Mackillop W. Defining the need for radiotherapy for lung cancer in the general population: a benchmarking approach. Med Care 41 9 (2003) 1074-1085
23. Murray N., Coy P., Pater J., Hodson I., Arnold A., Zee B., et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage SCLC. J Clin Oncol 11 2 (1993) 336-344
24. Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 23 (1992) 1618-1624
25. Saunders M., Dische S., Barrett A., Harvey A., Griffiths G., and Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial CHART Steering committee. Radiother Oncol 52 2 (1999) 137-148
26. Janssen-Heijnen M.L., Houterman S., Lemmens V.E., Louwman M.W., and Coebergh J.W. Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res 124 (2005) 89-107
27. de Rijke J.M., Schouten L.J., ten Velde G.P., Wanders S.L., Bollen E.C., Lalisang R.I., et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with NSCLC; results of a population-based study. Lung Cancer 46 2 (2004) 233-245
28. Potosky A.L., Saxman S., Wallace R.B., and Lynch C.F. Population variations in the initial treatment of NSCLC. J Clin Oncol 22 16 (2004) 3261-3268
29. Yeole B.B., and Kumar A.V. Population-based survival from cancers having a poor prognosis in Mumbai, India. Asian Pac J Cancer Prev 5 2 (2004) 175-182
30. Sharp L., and Brewster D. The epidemiology of lung cancer in Scotland: a review of trends in incidence, survival and mortality and prospects for prevention. Health Bull 57 5 (1999) 318-331
31. Woods L.M., Rachet B., and Coleman M.P. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol 17 1 (2006) 5-19
32. Gorey K.M., Holowaty E.J., Fehringer G., Laukkanen E., Richter N.L., and Meyer C.M. An international comparison of cancer survival: relatively poor areas of Toronto Ontario and three US metropolitan areas. J Public Health Med 22 3 (2000) 343-348
33. Bradley C.J., Gardiner J., Given C.W., and Roberts C. Cancer Medicaid enrollment and survival disparities. Cancer 103 8 (2005) 1712-1718
34. Campling B.G., Hwang W.T., Zhang J., Thompson S., Litzky L.A., Vachani A., et al. A population-based study of lung carcinoma in Pennsylvania: comparison of Veterans Administration and civilian populations. Cancer 104 4 (2005) 833-840
35. Bach P., Cramer L., Warren J., and Begg C. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341 16 (1999) 1198-1205
36. Brewster D.H., Thomson C.S., Hole D.J., Black R.J., Stroner P.L., and Gillis C.R. Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. Br Med J 322 7290 (2001) 830-831
37. Schrijvers C.T., Coebergh J.W., and Mackenbach J.P. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer 80 8 (1997) 1482-1488
38. Levin K. Urban-rural differences in self-reported limiting long-term illness in Scotland. J Public Health Med 25 4 (2003) 295-302
39. Stockton D. Cancer survival In Scotland: understanding social variations (2001), University of London
40. Buccheri G., and Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur Respir J 24 6 (2004) 898-904
41. Myrdal G., Lambe M., Hillerdal G., Lamberg K., Agustsson T., and Stahle E. Effect of delays on prognosis in patients with NSCLC. Thorax 59 1 (2004) 45-49
42. Quarterman R., McMillan A., Ratcliffe M., and Block M. Effect of preoperative delay on prognosis for patients with early stage NSCLC. J Thorac Cardiovasc Surg 125 1 (2003) 108-113
43. Tammemagi C.M., Neslund-Dudas C., Simoff M., and Kvale P. Lung carcinoma symptoms-an independent predictor of survival and an important mediator of African-American disparity in survival. Cancer 101 7 (2004) 1655-1663
44. Gadgeel S.M., and Kalemkerian G.P. Racial differences in lung cancer. Cancer Metastasis Rev 22 1 (2003) 39-46
45. Tammemagi C.M., Neslund-Dudas C., Simoff M., and Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 125 1 (2004) 27-37
46. Fox J., Rosenzweig K., and Ostroff J. The effect of smoking status on survival following radiation therapy for NSCLC. Lung Cancer 44 3 (2004) 287-293
47. Skuladottir H., Tjoenneland A., Overvad K., Stripp C., and Olsen J.H. Does high intake of fruit and vegetables improve lung cancer survival?. Lung Cancer 51 3 (2006) 267-273
48. Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., Tolonen H., Ruokokoski E., and Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from WHO MONICA project. Lancet 353 9164 (1999) 1547-1557
49. Janssen-Heijnen M.L., Schipper R.M., Razenberg P.P., Crommelin M.A., and Coebergh J.W. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 21 2 (1998) 105-113
50. Clegg L.X., Li F.P., Hankey B.F., Chu K., and Edwards B.K. Cancer survival among US whites and minorities: a SEER Program population-based study. Arch Intern Med 162 17 (2002) 1985-1993
51. Lathan C., Neville B., and Earle C. The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol 24 3 (2006) 413-418
52. Mulligan C., Meram A., Proctor C., Wu H., Zhu K., and Marrogi A. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomarkers Prev 15 1 (2006) 25-31
53. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I., et al. Clinical and biological features associated with EGFR gene mutations in lung cancers. J Natl Cancer Inst 97 5 (2005) 339-346
54. Thomas J., Lamb D., Ashcroft T., Corrin B., Edwards C., Gibbs A., et al. How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. Thorax 48 11 (1993) 1135-1139
55. Foegle J., Hedelin G., Lebitasy M.P., Purohit A., Velten M., and Quoix E. Non-small-cell lung cancer in a French department (1982-1997): management and outcome. Br J Cancer 92 3 (2005) 459-466
56. Strand T.E., Rostad H., Møller B., and Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 61 8 (2006) 710-715
57. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 8 (2002) 816-824
58. Potti A., Mukherjee S., Petersen R., Dressman H., Bild A., Koontz J., et al. A genomic strategy to refine prognosis in early-stage NSCLC. N Engl J Med 355 6 (2006) 570-580
59. Zhu C., Shih W., Ling C., and Tsao M. Immunohistochemical markers of prognosis in NSCLC: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59 8 (2006) 790-800
60. Gilmore J. Report on smoking in Canada 1985-2001 (2002), Statistics Canada, Ottawa
61. Pearce J., Boyle P., and Flowerdew R. Predicting smoking behaviour in census output areas across Scotland. Health Place 9 2 (2003) 139-149
62. Jedrychowski W., Becher H., Wahrendorf J., Basa-Cierpialek Z., and Gomola K. Effect of tobacco smoking on various histological types of lung cancer. J Cancer Res Clin Oncol 118 4 (1992) 276-282
63. Gritz E., Dresler C., and Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 14 10 (2005) 2287-2293
64. Storm H., Dickman P., Engeland A., Haldorsen T., and Hakulinen T. Do morphology and stage explain the inferior lung cancer survival in Denmark?. Eur Respir J 13 2 (1999) 430-435
65. Erridge S., Murray B., Price A., Ironside J., Little F., Mackean M., et al. Improved treatment and survival for lung cancer patients in South-East Scotland. J Thorac Oncol 3 5 (2008) 491-498
66. Vinod S.K., Hui A.C., Esmaili N., Hensley M.J., and Barton M.B. Comparison of patterns of care in lung cancer in three area health services in New South Wales Australia. Intern Med J 34 12 (2004) 677-683
67. Brooks D., Klint A., Dickman P., Stahle E., and Lambe M. Temporal trends in NSCLC survival in Sweden. Br J Cancer 96 3 (2007) 519-522
68. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of SCLC in the United States over the last 30 years: analysis of the SEER database. J Clin Oncol 24 28 (2006) 4539-4544